Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial

被引：0
|
作者：
Wolisnky, J. S. [1 ]
Brochet, B. [2 ]
Montalban, X. [3 ,4 ]
Naismith, R. T. [5 ]
Manfrini, M. [6 ]
Garas, M. [6 ]
Villoslada, P. [7 ]
Model, F. [6 ]
Hubeaux, S. [6 ]
Kappos, L. [8 ]
Hauser, S. L. [9 ]
机构：
[1] UTHealth, McGovern Med Sch, Houston, TX USA
[2] Univ Bordeaux, Bordeaux, France
[3] Univ Toronto, Div Neurol, Toronto, ON, Canada
[4] Vall dHebron Univ Hosp, Barcelona, Spain
[5] Washington Univ, Sch Med, St Louis, MO USA
[6] F Hoffmann La Roche Ltd, Basel, Switzerland
[7] Genentech Inc, San Francisco, CA 94080 USA
[8] Univ Basel, Univ Hosp Basel, Basel, Switzerland
[9] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷
基金：
新加坡国家研究基金会;
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P910
引用
收藏
页码：490 / 491
页数：2
相关论文
共 50 条
  • [21] Sustained reduction in 48-week confirmed disability progression in patients with PPMS treated with ocrelizumab in the ORATORIO OLE: 8-year follow-up
    Wolinsky, J. S.
    Vermersch, P.
    Hartung, H. -P.
    Naismith, R. T.
    Airas, L.
    Townsend, B.
    Schneble, H. -M.
    Overell, J.
    Sauter, A.
    Wang, Q.
    Prajapati, K.
    Kappos, L.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 101 - 102
  • [22] Evaluation of no evidence of progression using composite disability outcome measures, in patients with primary progressive multiple sclerosis in the ORATORIO trial.
    Montalban, X.
    Arnold, D. L.
    Bar-Or, A.
    De Seze, J.
    Giovannoni, G.
    Hemmer, B.
    Rammohan, K.
    Masterman, D.
    Bernasconi, C.
    Wei, W.
    Belachew, S.
    Chin, P.
    Wolinsky, J.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 50 - 51
  • [23] Brain MRI Activity and Atrophy Measures in Patients Receiving Continuous Ocrelizumab or Switching From Interferon Beta-1a to Ocrelizumab Therapy in the Open-Label Extension Period of the Phase III Trials of Ocrelizumab in Patients With Relapsing Multiple Sclerosis
    Arnold, Douglas
    Kappos, Ludwig
    Hauser, Stephen
    Montalban, Xavier
    Traboulsee, Anthony
    Wolinsky, Jerry
    Levesque, Victoria
    Villoslada, Pablo
    Belachew, Shibeshih
    Model, Fabian
    Hubeaux, Stanislas
    Bar-Or, Amit
    NEUROLOGY, 2018, 90
  • [24] Dimethyl fumarate treatment of primary progressive multiple sclerosis: results of an open-label extension study
    Talbot, Jacob
    Lundell, Henrik
    Marstrand, Lisbet
    Madsen, Camilla Gobel
    Hansen, Malene Bredahl
    Siebner, Hartwig Roman
    Sellebjerg, Finn
    Chow, Helene Hojsgaard
    Sondergaard, Helle Bach
    Sorensen, Per Solberg
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 70
  • [25] EVALUATION OF NO EVIDENCE OF PROGRESSION OR ACTIVE DISEASE (NEPAD) IN PATIENTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS IN THE ORATORIO TRIAL
    Wolinsky, Jerry
    Montalban, Xavier
    Kappos, Ludwig
    Hauser, Stephen
    Giovannoni, Gavin
    de Seze, Jerome
    Bar-Or, Amit
    Masterman, Donna
    Bernasconi, Corrado
    Wei, Wei
    Garren, Hideki
    Chin, Peter
    Belachew, Shibeshih
    Arnold, Doug L.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2017, 88 (05):
  • [26] Open-label Phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS
    Kuhelj, R.
    Deol-Bhullar, G.
    Garas, M.
    Chin, P.
    Hauser, S.
    Montalban, X.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 200 - 200
  • [27] Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial
    Montalban, X.
    Wolinsky, J.
    Kappos, L.
    Hauser, S. L.
    Giovannoni, G.
    de Seze, J.
    Bar-or, A.
    Masterman, D.
    Bernasconi, C.
    Wei, W.
    Garren, H.
    Chin, P.
    Belachew, S.
    Arnold, D. L.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 576 - 576
  • [28] Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial
    Montalban, Xavier
    Wolinsky, Jerry
    Kappos, Ludwig
    Hauser, Stephen L.
    Giovannoni, Gavin
    de Seze, Jerome
    Bar-Or, Amit
    Masterman, Donna
    Bernasconi, Corrado
    Wei, Wei
    Garren, Hideki
    Chin, P.
    Belachew, S.
    Arnold, D. L.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (02) : NP10 - NP10
  • [29] Interim analysis of an open-label extension study of sustained release fampridine in patients with multiple sclerosis
    Goodman, A. D.
    Brown, T.
    Krupp, L.
    Schapiro, R.
    Marinucci, L.
    Cohen, R.
    Blight, A.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S13 - S13
  • [30] Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients with Primary Progressive Multiple Sclerosis in the ORATORIO Trial
    Wolinsky, Jerry
    Montalban, Xavier
    Kappos, Ludwig
    Hauser, Stephen
    Giovannoni, Gavin
    de Seze, Jerome
    Bar-Or, Amit
    Masterman, Donna
    Bemasconi, Corrado
    Wei, Wei
    Garren, Hideki
    Chin, Peter
    Belachew, Shibeshih
    Arnold, Douglas
    NEUROLOGY, 2017, 88
12345